Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC180913 | PMC |
| http://dx.doi.org/10.1128/br.21.4.259-262.1957 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The international symposium ASOBIOTICS 2024 brought together scientists across disciplines to discuss the challenges of advancing antibacterial antisense oligomers (ASOs) from basic research to clinical application. Hosted by the Helmholtz Institute for RNA-based Infection Research (HIRI) in Wurzburg, Germany, on September 12-13th, 2024, the event featured presentations covering major milestones and current challenges of this antimicrobial technology and its applications against pathogens, commensals, and bacterial viruses. General design principles and modification of ASOs based on peptide nucleic acid (PNA) or phosphorodiamidate-morpholino-oligomer (PMO) chemistry, promising cellular RNA targets, new delivery technologies, as well as putative resistance mechanisms were discussed.
View Article and Find Full Text PDFAssessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England.
Appl Health Econ Health Policy
January 2025
Centre for Health Economics, University of York, Alcuin 'A' Block, Heslington, York, YO10 5DD, UK.
Objectives: The UK has recently established subscription-payment agreements for two antimicrobials: cefiderocol and ceftazidime-avibactam. This article summarises the novel value assessments that informed this process and lessons learned for future pricing and funding decisions.
Methods: The evaluations used decision modelling to predict population incremental net health effects (INHEs), informed by systematic reviews, evidence syntheses, national surveillance data and structured expert elicitation.
Insights from the 2023 International Veterinary Immunology Symposium: global perspectives at Kruger National Park.
Vet Res
November 2024
Future Production: Chemicals, CSIR, Pretoria, 0002, South Africa.
The 13th International Veterinary Immunology Symposium (IVIS) was initially due to take place in August 2022, but as many things in our lives, the COVID-19 pandemic that hit the world two years prior, forced the organising committee to postpone the meeting until November 2023. As it is tradition, the veterinary immunology symposium was organised as a satellite meeting of the IUIS International Congress of Immunology, which in 2023 took place in Cape Town, and it is where veterinary immunologists from all over the world get together to discuss advances and challenges in the field of animal health. The 2023 International Veterinary Immunology Symposium (IVIS) was held from November 17th to 21st at Kruger National Park, Skukuza, South Africa.
View Article and Find Full Text PDFProceedings of the United Kingdom Periprosthetic Joint Infection Meeting 2022: Fracture-Related Infection Session.
Injury
November 2024
Department of Trauma and Orthopaedics, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Implant-related infections represent a relatively common and significant challenge in the surgical management of musculoskeletal trauma patients. The third United Kingdom Periprosthetic Joint Infection (UK PJI) Meeting convened in Glasgow on 1 April 2022, and brought together over 180 delegates, representing orthopaedics, infectious diseases, microbiology, plastic surgery, anaesthetics, and allied health professions, including pharmacy and specialist nurses. The meeting comprised a plenary session for all delegates, and separate breakout sessions for fracture-related infection (FRI) and arthroplasty.
View Article and Find Full Text PDFSerotype 15C Streptococcus pneumoniae resistant to classical complement deposition and agglutination by polyclonal rabbit anti-capsular 15B sera.
Vaccine
December 2024
Boston Medical Center, Boston, MA, USA; BU Chobanian and Avidesian School of Medicine, Boston, MA, USA; Rambam Health Care Campus, Haifa, Israel; Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Background: S. pneumoniae (SP) serotypes 15B and 15C are frequent causative agents of invasive pneumococcal disease (IPD), otitis media, and nasopharyngeal colonization in the post PCV13 era. The principal difference between serotypes 15B and 15C is the presence of an O-acetyl group on the pentasaccharide repeating unit of 15B polysaccharide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!